Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex net income
Net income is the profit left for shareholders after every expense, interest and tax.
Scilex's net income for the twelve months ending Jun 30, 2026 was -$464.56M. For fiscal 2025 it was -$374.05M. The highest annual figure on record is -$23.36M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$374.05M | – |
| FY2024 | Dec 31, 2024 | -$72.81M | – |
| FY2023 | Dec 31, 2023 | -$114.33M | – |
| FY2022 | Dec 31, 2022 | -$23.36M | – |
| FY2021 | Dec 31, 2021 | -$88.42M | – |
| FY2020 | Dec 31, 2020 | -$47.52M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$114.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.11M | – |
| Q3 FY2025 | Sep 30, 2025 | -$257.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.53M | -265.2% |
| Q2 FY2023 | Jun 30, 2023 | -$26.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.88M | – |
| Q3 FY2022 | Sep 30, 2022 | $21.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.14M | -788.0% |
| Q4 FY2021 | Dec 31, 2021 | -$88.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$233.75K | – |
| Q1 FY2021 | Mar 31, 2021 | $1.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$856 | – |